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VaccineAntibody-mediated capture of amyloid-beta (Aβ) in peripheral blood was identiﬁed as an attractive strategy to
eliminate cerebral toxic amyloid inAlzheimer's disease (AD) patients andmurinemodels. Alternatively, defective
capacity of peripheral monocytes to engulf Aβwas reported in individuals with AD. In this report, we developed
different approaches to investigate cellular uptake and phagocytosis of Aβ, and to examine how two immunolog-
ical devices – an immunostimulatory Adjuvant System and different amyloid speciﬁc antibodies – may affect
these biological events. Between one and thirteen months of age, APPswe X PS1.M146V (TASTPM) AD model
mice had decreasing concentrations of Aβ in their plasma. In contrast, the proportion of blood monocytes con-
taining Aβ tended to increase with age. Importantly, the TLR-agonist containing Adjuvant System AS01B primed
monocytes to promote de novo Aβ uptake capacity, particularly in the presence of anti-Aβ antibodies. Biochem-
ical experiments demonstrated that cells achieved Aβ uptake and internalization followed by Aβ degradation via
mechanisms that required effective actin polymerization and proteolytic enzymes such as insulin-degrading
enzyme. We further demonstrated that both Aβ-speciﬁc monoclonal antibodies and plasma from Aβ-
immunized mice enhanced the phagocytosis of 1 μm Aβ-coated particles. Together, our data highlight a new
biomarker testing to follow amyloid clearance within the blood and a mechanism of Aβ uptake by peripheral
monocytes in the context of active or passive immunization, and emphasize on novel approaches to investigate
this phenomenon.
© 2015GSKGroup of Companies. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).isease; APP, amyloid precursor
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Alzheimer's disease (AD) is a neurodegenerative disorder that
manifests as memory deterioration and cognitive impairment. AD is
the most common form of dementia worldwide, affecting over 37 mil-
lion people (Raﬁi and Aisen, 2009), and is the sixth leading cause of
death in the United States (Thies and Bleiler, 2013). Available
treatments only temporarily alleviate the symptoms and have shown
variable effectiveness (Thies and Bleiler, 2013). There is currently no
remedy that stops or reverses disease progression (Thies and Bleiler,
2013).
Amyloid plaques and neuroﬁbrillary tangles are histopathological
hallmarks characterizing AD patients' brains (Small and Duff, 2008).
The principal protein component of these amyloid plaques, the
amyloid-beta (Aβ) peptide, is generated by the cleavage of the amyloidrticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to the Aβ peptide within the native APP encompass part of the APP
transmembrane domain (Haass and Selkoe, 2007). Therefore, APP pro-
teolysis liberates the Aβ peptide and exposes hydrophobic amino
acids and regions otherwise hidden in the intact protein (Sgarbossa,
2012). Self-association of free Aβ generates amorphous structures
with granular morphology, oligomers, and ﬁbrillar aggregates (Pryor
et al., 2012; Sgarbossa, 2012). Interestingly, soluble Aβ intermediate
assemblies, such as oligomers, were shown to interfere with long-
term potentiation and cognitive performances in rat models (Haass
and Selkoe, 2007; Selkoe, 2008). The accumulation of Aβ also facilitates
the hyperphosphorylation and aggregation of the microtubule-
associated protein tau, resulting in the formation of neuroﬁbrillary
tangles (Weiner and Frenkel, 2006; Holtzman, 2008; Small and Duff,
2008). Mutations in APP, as well as in presenilin-1 (PS-1) and -2
(PS-2), can trigger this sequence of biochemical events, which leads to
early-onset AD (EOAD) (Small and Duff, 2008; Thies and Bleiler,
2013). Importantly, Jonsson et al. (2012) identiﬁed an amino acid sub-
stitution in APP that reduces APP processing and confers protection
against AD (Jonsson et al., 2012), supporting a potential link between
Aβ accumulation and AD. Even though the exact causes of late-onset
AD (LOAD) have yet to be determined, Aβ is thought to play a critical
role in the development of this disease.
The predominance of the amyloid hypothesis has stimulated the
development of drugs preventing the proteolysis of APP, or the secre-
tion or aggregation of Aβ (Raﬁi and Aisen, 2009). However, precluding
Aβ production may not be the only strategy of treating AD. An effective
alternative could be to stimulate the immune system in order to
neutralize or eliminate a toxic overload of Aβ. Evidences supporting
this possibility were reported by Mawuenyega et al. (2010), who
demonstrated that LOAD patients have a general impairment in Aβ
clearance rather than increased Aβ production (Mawuenyega et al.,
2010). Several studies performed in murine AD models suggest that
vaccination with Aβ antigens and injection of anti-Aβ antibodies could
prevent the accumulation of Aβmolecules and the formation of plaques,
and improve cognitive performance (Schenk et al., 1999; Games et al.,
2000; Arendash et al., 2001; Bacskai et al., 2001; Zhang et al., 2003;
Jensen et al., 2005; Maier et al., 2006; Spires-Jones et al., 2009). Howev-
er, phase II clinical trials involving the vaccine AN1792 were curtailed
because 6% of patients immunized with Aβ42 presented symptoms of
meningoencephalitis (Orgogozo et al., 2003). Immunogenic T-cell
epitopes were identiﬁed in the central part of Aβ and were postulated
as being responsible of these harmful effects (Monsonego et al., 2006;
Toly-Ndour et al., 2011). Nevertheless, when these patients were
followed up using the neuropsychological test battery, antibody re-
sponders were shown to have improved cognitive functions compared
with placebo (Gilman et al., 2005; Vellas et al., 2009). In addition,
post-mortem examination of patients treated with AN1792 showed
reduced plaque formation and improved neurite morphology in the
brain (Nicoll et al., 2003; Ferrer et al., 2004; Masliah et al., 2005;
Holmes et al., 2008; Serrano-Pozo et al., 2010). These encouraging
observations support further research into the design of an effective
and safe immunotherapy for AD. CAD106, ACC-001 and Afﬁtope AD02
are among the second-generation of Aβ-targeting active vaccines in
humans, using short N-terminal amyloid antigens such as Aβ1–6, and
will, hopefully, minimize adverse side effects and improve disease
prognosis (Panza et al., 2014; Arai et al., 2015).
The Aβ peptide was detected in plasma samples from patients
examined in several studies (Tamaoka et al., 1996; Mayeux et al., 1999,
2003; Assini et al., 2004; Schupf et al., 2008; Devanand et al., 2011). Fur-
thermore, individuals with high baseline Aβ42 levels were more likely to
develop AD (Mayeux et al., 1999, 2003; Schupf et al., 2008). Among par-
ticipants who developed AD, plasma levels of Aβ42 diminished concomi-
tantly with the onset of cognitive defects as well as the increased
binding of Pittsburgh compound B (PiB) to the brain (Schupf et al.,
2008; Devanand et al., 2011). The presence of Aβ in the plasma impliesa peptide outﬂow from the brain, whereas blood was proposed to serve
as a source of Aβ that would ﬂow into the encephalon to elicit toxicity
(Clifford et al., 2007). This possible dynamic between the blood-stream
and the brain led to the peripheral sink hypothesis. Accordingly, peripher-
al administration of anti-Aβ antibodies to PDAPP (APPV717F) transgenic
mouse led to a rapid increase of Aβ in the plasma, which reﬂected levels
of amyloid deposition in the brain (DeMattos et al., 2001, 2002). This po-
tential dynamic between blood and brain Aβ levels may be critical for ef-
ﬁcient active and passive immunization, as well as other therapies
involving the capture of disseminating Aβ. Nonetheless, themolecular se-
questration of Aβmay not be sufﬁcient for its complete elimination or for
amelioration of the disease prognosis. Interestingly, macrophages from
AD patients have shown defective phagocytosis of Aβ (Fiala et al.,
2005). Alternatively, monophosphoryl lipid A (MPL)-mediated Toll-like
receptor 4 (TLR4) stimulation promoted the expansion of monocytes
and their uptake of Aβ, which correlated with the reduction of cerebral
Aβ load and improved cognitive performance in murine models
(Michaud et al., 2013). Strategies aimed at capturing and stimulating
cell-mediated elimination of Aβmay therefore also be important in gen-
erating an effective immunotherapy. Notably, assessing and following the
cellular activities involved in Aβ clearance will beneﬁt the development
and characterization of such treatment.
Here, we propose novel procedures to explore cellular Aβ uptake
mechanisms and phagocytosis of larger amyloid particles. Using
in vivo, ex vivo and in vitro systems, we observed that amyloid speciﬁc
antibodies promoted efﬁcient uptake and phagocytosis of Aβ. In addi-
tion, we explored the effect of combining anti-Aβ antibodies with the
MPL-containing Adjuvant System AS01B. Importantly, AS01B treatment
activated blood monocytes to multiply their Aβ uptake activity in
presence of antibodies. Also, our data show that cells engulﬁng Aβ are
likely capable of degrading this peptide. This phenomenon involved
the protease insulin-degrading enzyme (IDE). We believe that our
approach will beneﬁt the development of future immunotherapies for
AD and of blood biomarkers to monitor their efﬁciency.
2. Materials and methods
2.1. Reagents and cell culture
Chemicals were from Sigma-Aldrich, Fisher Scientiﬁc and Thermo Sci-
entiﬁc; Aβ peptides from AnaSpec; and paraformaldehyde, from Electron
Microscopy Sciences (EMS). To characterize cells by ﬂow cytometry, we
used the following antibodies from BD Pharmingen: Fc block (rat
anti-mouse CD16/CD32, clone 2.4G2, cat # 553142), PE rat anti-mouse
Ly-6G (clone 1A8, cat # 551461), PE mouse-anti mouse NK-1.1 (clone
PK136, cat # 553165), PE rat anti-mouse CD45/B220 (clone RA3-6B2,
cat # 553090), PE hamster anti-mouse CD3e (clones 145-2C11,
cat # 553064), V450 rat anti-mouse Ly-6C (clones AL-21, cat # 560594),
APC rat anti-mouse CD11b (clone M1/70, cat # 553312) and PerCP-
Cy5.5 rat anti-mouse I-A/I-E (MHC class II, clone M5/114.15.2, cat #
562363). The 2E7 anti-Aβ antibody was generated by GSK Pharma. This
antibody is an IgG2a that recognizes the ﬁrst seven amino acids of Aβ.
THP-1 cellswere cultured in Roswell ParkMemorial Institute (RPMI)
1640 medium supplemented with 2 mM L-glutamine, 0.05 mM
2-mercaptoethanol, 100 U/mL penicillin, 100 μg/mL streptomycin and
10% fetal bovine serum (FBS), referred to as complete RPMI. BV2 cells
were cultured in Dulbecco's Modiﬁed Eagle Medium (DMEM) supple-
mented with 1× sodium pyruvate, 100 U/mL penicillin, 100 μg/mL
streptomycin and 10% FBS. Media and additives used in cell culture
were from Gibco. Both cell lines were incubated at 37 °C in a 5% CO2
humid atmosphere.
2.2. Animals
Procedures involving animals were executed accordingly to the
guidelines of the Canadian Council on Animal Care (CCAC) in science.
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Transgenic mice (TASTPM) expressing the APP and the PS-1 genes
were described previously (Richardson et al., 2003; Howlett et al.,
2004).
2.3. Enzyme-linked immunosorbent assay (ELISA)
StreptAvidin immobilizer plates (VWR)were coatedwith sodiumcar-
bonate buffer (50 mM Na2CO3, pH9.6) supplemented with 0.5 μg/mL
Aβ1–42-biotin (Anaspec) for 16 h at 4 °C. Plates were then washed with
phosphate-buffered saline (PBS) supplemented with 0.05% Tween 20
(PBS-T), incubated for 1 h at 37 °Cwith super block solution (ScyTek Lab-
oratories Inc.) and incubated for an additional 2 h at 37 °C with samples
and controls diluted in super block. Reactions were washed with PBS-T,
incubatedwith horseradish peroxidase (HRP) conjugated anti-mouse an-
tibodies (Jackson Immuno Research Laboratories, Inc.) prepared in super
block for 1 h at 37 °C and washed with PBS-T. Washes were performed
using a Skan Stacker 300 (Skatron Instrument). For antibody detection,
TMB substrate (BD OptEIA) prepared accordingly to the manufacturer's
instructions was added and incubated for 30 min at room temperature.
Reactions were stopped using 2 N H2SO4, and products were detected
and analyzed using the Spectra max 340PC384 (Molecular Devices) and
the Soft Max Pro software (Molecular Devices).
2.4. Preparation of cellular extracts and immunoblotting analyses
The effect of pharmacological inhibitors targeting the cytoskeleton
and the distinction between Aβ adhering to the surface versus internal-
ized peptide were determined using the following procedures. On the
day preceding the assay, BV2 cells were counted using the EasyCount
ViaSure kit and the EasyCount system (Immunicon), and seeded at
9 × 105 cells per 60 mm cell culture dish. Next, cells were incubated
with vehicle media or media containing 5 μg/mL cytochalasin D
(Calbiochem) for 30 min prior being exposed to vehicle media or
1 μg/mL Aβ with or without 1 μg/mL anti-Aβ antibodies (2E7). Cells
were incubated for another 15 or 60 min as indicated (Supplementary
Fig. 4). Cell extracts were then prepared from either non-trypsinized
or trypsinized cells. In the case of non-trypsinized cells, dishes were
placed on ice and cells were rinsed with ice-cold PBS and solubilized
for 15 min in lysis buffer (100 mM Tris–HCl pH7.4, 5 mM EDTA,
150 mM NaCl, 1% Triton X-100, 0.1% SDS, 50 mM NaF, 1 mM Na3VO4
and Complete protease inhibitor (Roche)) (Hallé et al., 2009).
Cell extracts were cleared by centrifugation at 16,000 × g for 10 min at
4 °C. Trypsinized cells were rinsed with PBS, incubated with
0.05% trypsin-EDTA (Gibco) for two minutes at 37 °C, resuspended in
complete DMEM and centrifuged at 850 × g for 3 min. Cell pellets
werewashedwith ice-cold PBS, centrifuged anddissociated in lysis buff-
er. Cell extracts were cleared by centrifugation at 16,000 × g for 10 min
at 4 °C. Protein concentration of each sample was measured using the
Bradfordmethod (Coomassie Plus— The Better Bradford Assay Reagent,
Thermo Scientiﬁc) and 20 μg of protein from cellular lysates were sepa-
rated using tris-tricine gels (BioRad) as previously described (Schagger,
2006). Separated proteins were then transferred onto polyvinylidene
diﬂuoride membranes. Membranes were boiled in PBS for 10 min,
blocked in tris-buffered saline-Tween 20 and probed with identiﬁed
antibodies according to themanufacturer's instructions. Signalswere re-
vealed using the SuperSignal® West Dura Extended Duration Substrate
(Thermo Scientiﬁc) and detected on Amersham Hyperﬁlm™.
The stability of Aβ taken up by BV2 cells was examined as follows:
cells were incubated with vehicle media, media containing 1 μg/mL
Aβ or 1 μg/mL Aβ with 1 μg/mL anti-Aβ antibodies (2E7) for 30 min.
Media was removed and cells were rinsed with PBS and then incubated
in complete DMEM without Aβ or anti-Aβ antibodies for indicated
time periods. Cells were subsequently washed, lysed and analyzed by
immunoblotting as described above.The ability of pharmacological protease inhibitor to hinder
cell-mediated degradation of Aβ was investigated as follows: BV2
cells were incubated for 30 min with or without 500 μM 1,10-
phenanthroline, a pre-speciﬁed concentrations (Sudoh et al., 2002).
Cells were then incubated for an additional 30 min under the following
conditions: vehicle media, media containing 1 μg/mL Aβ or 1 μg/mL Aβ
with 1 μg/mL anti-Aβ antibodies (2E7) with or without 500 μM 1,10-
phenanthroline. Cells were rinsed with PBS to remove unbound Aβ and
were further incubated for 1 or 3 h with complete DMEM or with
media supplemented with the appropriate inhibitor when applicable.
Cells were then detached using trypsin, lysed and analyzed by immuno-
blotting using the procedures described above.
2.5. Quantiﬁcation of Aβ in plasma
Blood from WT C57BL/6 and TASTPM transgenic mice of identiﬁed
ages were collected, transferred to EDTA tubes and mixed by inversion
to prevent coagulation. Blood samples were then centrifuged at
3200 × g for 8 min at 4 °C, and plasma supernatants were transferred
to fresh tubes and kept frozen until analysis. The concentrations of
Aβ40 and Aβ42 were measured using the MSD 96-Well Multi-Spot
Human (4G8) Aβ Triplex Assay and the Sector Imagor 6000 apparatus
fromMeso Scale Discovery according to the manufacturer's instructions.
2.6. Intracellular staining of Aβ
Bloodwas withdrawn fromWT C57BL/6 and TASTPMmice via cardi-
ac puncture and transferred to EDTA tubes. Then, blood samples (250 μL)
were transferred to a conical-bottom 96-well plate (Nunc), centrifuged
at 250× g for 5min,washedwith 200 μL FACS stainingbuffer (Dulbecco's
Phosphate Buffered Saline (DPBS) supplemented with 0.5% bovine
serum albumin (BSA), 5 mM EDTA and 0.09% sodium azide) and centri-
fuged at 250× g for 5min. Next, blood cellswere incubatedwith rat anti-
mouse CD16/CD32 antibodies at a ﬁnal dilution of 1/100 for 10min, and
were further incubated for 30minwith PE hamster anti-mouse CD3e, PE
rat anti-mouse CD45R/B220, PE rat anti-mouse Ly-6G, PE mouse anti-
mouse NK-1.1 and APC rat anti-mouse CD11b antibodies at respective
ﬁnal dilutions of 1/100, 1/500, 1/250, 1/250 and 1/500. Cells were then
washed with 150 μL FACS staining buffer, incubated for 20 min with
200 μL CytoFix/CytoPerm solution (BD) on ice and protected from light,
centrifuged at 250 ×g for 5 min, washedwith 200 μL 1× Perm/Wash so-
lution (BD) and centrifuged at 250 × g for 5 min. Treatment and washes
with these two solutions efﬁciently removed red blood cells (data not
shown), which eliminated the requirement of a step to lyse red-blood
cells. Cell pelletswere resuspended in 50 μL FACS staining buffer contain-
ingAlexa Fluor 488mouse anti-humanAβ (6E10) antibodies at aﬁnal di-
lution of 1/500, incubated in the dark at 4 °C for 30 min, washed with
200 μL 1× Perm/Wash solution, centrifuged at 250 × g for 5 min and
ﬁnally resuspended in 250 μL staining buffer. Controls, such as unstained,
single-color and ﬂuorescence minus one (FMOs), were also included in
the assay. Cells were analyzed using a FACS Canto II (BD) cytometer
and the FACSDiva software (BD).
2.7. Measure of cellular capacity to take up Aβ ex vivo
On day 0, two-month-old C57BL/6 female mice received an
intra-muscular (IM) injection (50 μL) of PBS, AS01B (1×) or Alum
(1 mg/mL). Terminal blood collections were performed 24 h post-
injection. Then, 80 μL of blood was transferred to propylene tubes and
received an additional 5 μL of one of the following reagents: vehicle
media or HiLyte Fluor 488-labeled Aβ42 (AnaSpec) (10 μg/mL) with or
without 2E7 anti-Aβ antibodies (10 μg/mL). In the dark, samples were
incubated for 90min at 37 °C in a 5% CO2 humid atmosphere and subse-
quently chilled on ice for 10 min. Then, 5 μL of Fc block (rat anti-mouse
CD16/CD32 antibodies diluted in FACS staining buffer) was added to
each sample at a ﬁnal dilution of 1/100, and samples were incubated
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antibody cocktail prepared in FACS staining buffer, which contained PE
rat anti-mouse Ly-6G, PE mouse anti-mouse NK-1.1, PE rat anti-mouse
CD45/B220, PE hamster anti-mouse CD3e, V450 rat anti-mouse Ly-6C,
APC rat anti-mouse CD11b and PerCP-Cy5.5 rat anti-mouse I-A/I-E anti-
bodies diluted at 1/250, 1/250, 1/500, 1/100, 1/100, 1/500 and 1/500, re-
spectively, in the ﬁnal volume. Samples were incubated for 30 min at
room temperature in the dark. After incubation, samples were mixed
with 2 mL of 1× RBC Lysis Buffer (multi species, eBioscience) and incu-
bated for 7 min at room temperature and protected from light. Ice-cold
DPBS (10mL) was added immediately after the incubation and samples
were centrifuged at 500 × g for 10 min and at 4 °C. Supernatants were
removed, and cell pellets were resuspended in 90 μL DPBS containing
LIVE/DEAD Fixable Aqua reagent (Molecular Probes, Life Technologies),
which was prepared and diluted according to the instructions from the
manufacturer. Cells were incubated for 30min on ice in the dark. Subse-
quently, cells were resuspended in 1mL 2% paraformaldehyde/DPBS, in-
cubated for 10 min on ice in the dark, resuspended in an additional
10 mL ice-cold DPBS and centrifuged at 500 × g for 10 min at 4 °C. Cell
pellets were then resuspended in 250 μL FACS staining buffer and kept
at 4 °C in the dark. Controls, such as unstained, single-color and FMOs,
were also included in the assay. Finally, cells were analyzed by ﬂow cy-
tometry using a FACS Canto II (BD) and the FACSDiva software (BD).
2.8. Measure of cellular Aβ uptake capacity in vivo
Two-month-old C57BL/6 mice were initially immunized on day 0
and then on days 14, 21 and 28 via IM injection of PBS, AS01B alone,
Aβ1–6CRM (Aβ1–6 peptide conjugated to the non-toxic mutant form of
the diphtheria protein CRM197, which is used as a carrier), AS01B with
Aβ1–6CRM or Alum with Aβ1–6CRM. On day 29, animals received an
intra-venous (IV) injection of HiLyte Fluor 488-labeled Aβ (5 μg) via the
tail vein. Terminal blood collections were performed 2 h following the
IV injection. Then, 250 μL of collected blood was transferred into a
conical-bottom 96-well plate (Nunc). Plates were centrifuged at 300 × g
for 5 min, plasma was removed, and cells were resuspended in 100 μL
red blood cell lysing buffer (Sigma), incubated for 2 min and centrifuged
at 300× g for 5min. A second round of red blood cell lysis was performed
using the same procedures. Cell pellets were then washed with 200 μL
FACS staining buffer, centrifuged at 250 × g for 5 min and incubated for
10minwith 25 μL rat anti-mouseCD16/CD32antibodies at aﬁnal dilution
of 1/100. Cells were then incubated for 30 min with 25 μL of an antibody
cocktail containing PE hamster anti-mouse CD3e, PE rat anti-mouse
CD45R/B220, PE rat anti-mouse Ly-6G, PE mouse anti-mouse NK-1.1
and APC rat anti-mouse CD11b antibodies diluted at 1/100, 1/500, 1/
250, 1/250 and1/500, respectively, in theﬁnal volume. Cellswerewashed
twicewith 150 μL FACS staining buffer,ﬁxed in 2%paraformaldehyde-PBS
solution for 15 min in the dark, centrifuged at 250 × g for 5 min,
resuspended in 250 μL FACS staining buffer and kept at 4 °C protected
from light. Cells were analyzed by ﬂow cytometry using a FACS Canto II
(BD) and the FACSDiva software (BD).
2.9. Phagocytosis of Aβ-coated latex beads
Phagocytic activity was measured using a modiﬁed version of a
recently described protocol (Ackerman et al., 2011). One day prior to
the experiment, NeutrAvidin-labeled latex beads were coated with
biotin-conjugated Aβ42 as follows: 10 μL of a microsphere solution (1%
solid; NeutrAvidin-labeled 1 μm FluoSpheres from Life Technologies)
was transferred to a tube containing 900 μL DPBS, mixed and centri-
fuged at 17,949 × g for 5 min at 4 °C. The supernatant was discarded,
and the microspheres were washed with 1 mL DPBS supplemented
with 0.1% BSA fraction V (Gibco). The microspheres were resuspended
in 1 mL DPBS supplemented with 0.1% BSA and 10 μg Aβ1–42-biotin
(AnaSpec Inc.), and incubated at 4 °C with gentle agitation for 16 h.
The preparation was then centrifuged at 17,949 × g for 5 min at 4 °C,and the beads pellet was washed two more times with DPBS supple-
mented with 0.1% BSA, re-suspended in 1 mL 0.1% BSA/DPBS and kept
on ice in the dark until being processed for cellular assays. THP-1 cells
were centrifuged at 212 × g for 5 min, the supernatant was discarded,
and the cell pellet was re-suspended in complete RPMI. Cells were
counted using a hemacytometer (Hausser Scientiﬁc). 1.4 × 105 THP-1
cells were distributed in volumes of 100 μL in a round-bottom 96-well
tissue culture plate (Falcon). Next, 20 μL of the Aβ1–42-coated bead
suspension, plus plasma or 2E7 monoclonal antibodies were added in
a volume of 10 μL to obtain a ﬁnal concentration of 1 μg/mL in each
experimental well. Control cells, with or without latex beads, were
incubatedwith the appropriate quantity of vehiclemedia. Cells were in-
cubated at 37 °C in a 5% CO2 humid atmosphere for the indicated time
and transferred to a conical bottom plate (Nunc). Round-bottom
96-well plates were rinsed with 50 μL DPBS, and DPBS was transferred
to corresponding wells of the conical bottom plate. Cells were centri-
fuged at 212 × g for 5 min, resuspended in 150 μL DPBS, centrifuged at
212 × g for 5 min, resuspended in 50 μL 0.05% trypsin-EDTA, incubated
at 37 °C in a 5% CO2 humid atmosphere for 2min, resuspended in 150 μL
RPMI completemedia, centrifuged at 212× g for 5min and resuspended
in a 2% paraformaldehyde-PBS solution. Cells were then incubated on
ice and in the dark for 15min,washedwith 100 μL ice-cold DPBS, resus-
pended in 250 μL FACS staining buffer (DPBS supplemented with 0.5%
BSA, 5 mM EDTA and 0.09% sodium azide), transferred to a round-
bottom polystyrene tube, and analyzed by ﬂow cytometry using a
FACS Canto II (BD) and the FACSDiva software (BD).
Experiments to test different plasma samples from different animals
were performed as follows: Aβ1–42-coated latex beads and cells were
prepared and distributed in round-bottom 96-well tissue culture plates
as described above. Each well then received 2 μL of plasma samples or
control media, and plates were incubated for 2 h at 37 °C in a 5% CO2
humid atmosphere. Cells were then processed and analyzed as
described above. Plasma samples were obtained from C57BL/6 WT
female mice inoculated with 50 μL of a solution containing PBS or 1 μg
Aβ1–6CRM mixed with 1× AS01B. Mice were injected IM on days 0, 14
and 21, and blood was collected and processed to recover plasma as
described above on day 22.
2.10. Statistical analyses
We used ANOVAmethod on the base ten logarithm (log10) of values
using a heterogeneous model of variance. For Aβ intracellular staining
and in vivo Aβ uptake capacity, the analysis included one factor (condi-
tion). Analysis for the cellular capacity to take up Aβ ex vivo included
three factors (experiment, injected product and peptide/antibody). In-
teractions between the three factors as well as between the injected
product and the peptide/antibodywere examined. For the phagocytosis
of Aβ-coated beads, the analysis was performed using two factors
(antibody and time point). In the case of the phagocytosis assay using
plasma from different mice, the analysis included the factor condition
only. Estimates of the geometric mean ratios between groups and their
95% conﬁdence intervals (CI) were obtained using back-transformation
of the log10 values. Tukey's method was used to adjust for multiplicity.
3. Results
3.1. Peripheral monocytes take up Aβ produced in the brain of transgenic
animals
As TASTPMmice age, their Aβ-plaque burden increases and is associ-
ated with dystrophic neurites andmemory deﬁcit (Howlett et al., 2004).
To examine the presence of Aβ in the peripheral blood of this transgenic
model, we collected blood samples frommice of different ages and ana-
lyzed plasmas for amyloid peptide content. In one-month-oldmice, both
Aβ40 andAβ42 could already be detected (Fig. 1A). Levels of amyloid pep-
tides appeared to diminish as transgenicmice aged, but remained higher
Fig. 1. Peripheral blood monocytes capture Aβmolecules available in the blood of the TASTPM murine model. Blood from TASTPM mice of identiﬁed ages and from C57BL/6
WT mice was collected and analyzed for plasmatic Aβ40 and Aβ42 content (A) and cells were characterized by ﬂow cytometry (B, C, D, E). Monocytes were identiﬁed follow-
ing the successive selection of single cells, cells without debris and CD11b+/lineage− cells (B). Similar proportions of monocytes were found between the tested groups (C).
The proportion of Aβ-positive monocytes and the level of Aβ detected per positive cell, expressed as the GMFI, found in each tested mice are shown in D and E, respectively.
Data are representative of two independent experiments. Aβ was detected in monocytes from TASTPM transgenic mice in ﬁve other experiments involving animals that
were 5, 6, 7.5, 8.5 and 11.2 month-old. Individual mice were represented as circles (WT) and triangles (TASTPM). Means ± standard deviation (SD) are shown for each test-
ed condition.
68 M. Hallé et al. / Journal of Immunological Methods 424 (2015) 64–79in TASTPM than inWTmice at all tested ages (Fig. 1A). To investigate the
possible accumulation of Aβ in circulating immune cells, blood samples
were processed to stain cell-associated Aβ and cell-surface markers,Fig. 2. Immunotherapy, involving AS01B and an amyloid peptide, promotes peripheral monocy
following products: PBS, AS01B, Aβ1–6CRM, Aβ1–6CRM with AS01B or Aβ1–6CRM with Alum. On
later. Blood sampleswere then processed for the immunodetection of cell-surfacemarkers and a
anti-Aβ antibody content by ELISA (A). The proportion of cells expressing surfacemarkers chara
on the promotion of Aβ uptakewere compared (C). The proportions ofmonocytes that capture A
in D and E, respectively. Similar results were obtained in four independent experiments. Each poin
rescent Aβ. Mice injectedwith HiLyte Fluor 488 Aβ42 are associatedwith ﬁlled geometric shapes. C
Aβ1–6CRMwith AS01B or Aβ1–6CRM with Alum immunized groups, respectively. Means ± SD areandwere analyzed by ﬂow cytometry. Following the successive selection
of single cells and cells without debris, monocytes were identiﬁed as
CD11b-positive and lineage-negative (CD3e−, B220−, NK-1.1−, Ly-6G−)tes to take up Aβ in vivo. On days 0, 14, 21 and 28, mice were injected IM with one of the
day 29, mice received HiLyte Fluor 488 Aβ42 via the tail vein and blood was collected 2 h
nalyzedbyﬂow cytometry. Plasma samples from the same animalswere analyzed for their
cteristic ofmonocytes is shown for eachblood sample (B). The effects of various treatments
β and theGMFI of cells containingHiLyte Fluor 488 Aβ present in each animal are depicted
t represents an individualmouse. Open circles correspond to control mice not receiving ﬂuo-
ircles, squares, inverted triangle, triangle and diamond correspond to PBS, AS01B, Aβ1–6CRM,
shown for each tested conditions.
69M. Hallé et al. / Journal of Immunological Methods 424 (2015) 64–79events (Fig. 1B), as described previously (Mildner et al., 2007). TATPM
and WT mice had similar proportions of blood monocytes (Fig. 1C).
Immunodetection of Aβ revealed the presence of Aβ-positive monocytesin blood samples from the TASTPMmice, but not in those fromWTmice
(Fig. 1B). Thiswas also illustrated by the greater proportion ofmonocytes
positive for Aβ (pb 0.0001) and their increasedGMFI for Aβ (pb 0.001) in
70 M. Hallé et al. / Journal of Immunological Methods 424 (2015) 64–79TASTPM than inWTmice, for all tested ages (D, E). Interestingly, periph-
eral monocytes containing Aβ were already present in one-month-old
TASTPM mice. Their proportion and Aβ content were more elevated in
older mice. Accordingly, compared with 1-month-old TASTPM mice,
4.5-, 6.5- and 13-month-old TASTPM mice had a 2.86, 3.33 and 2.94
(p b 0.0001) fold increase in the percentage of Aβ-positive monocytes,
respectively (Fig. 1D) and a 1.39 (p b 0.0001), 1.67 (p b 0.0001) and
1.43 (p b 0.001) fold increase in the geometric mean of ﬂuorescence in-
tensity (GMFI) for Aβ per amyloid-positive monocyte (Fig. 1E). Similar
trends, but with lower percentages, were observed for total cells
(Supplementary Fig. 1). These data demonstrate that peripheral
monocytes from an AD animal model contain Aβ and suggest that
these cells are capable of capturing amyloid that diffuses from the
brain into the periphery.
3.2. Vaccination triggering the production of anti-Aβ antibodies and AS01B
immunostimulatory adjuvant stimulate the amyloid uptake capacity of
monocytes in vivo
Immunodetection of cell-associated amyloid does not allow de novo
Aβ uptake to be distinguished fromAβ thatmay have been accumulating
over a long period. To investigate amyloid peptide uptake capacity
of monocytes in the context of vaccination, C57BL/6WTmice were inoc-
ulated with PBS, AS01B alone, Aβ1–6CRM alone, Aβ1–6CRMwith AS01B or
Aβ1–6CRM with Alum on days 0, 14, 21 and 28. On day 29, we injected
ﬂuorescent Aβ intravenously into vaccinated mice, and analyzed their
bloodbyﬂowcytometry. Thedifferent treatments didnot signiﬁcantly in-
ﬂuence the proportion of cells expressing monocyte surface markers
(Fig. 2B), which were identiﬁed as described above (Fig. 1B). Proportions
of monocytes harboring ﬂuorescent Aβ were found to be higher in all
treated mice than in control mice not receiving Aβ (Fig. 2C, D). The pro-
portion of monocytes capturing Aβ was 3.87 (p = 0.029) and 4.55
(p = 0.0003) times higher in mice immunized with both Alum and
Aβ1–6CRM than in mice receiving PBS or Aβ1–6CRM alone, respectively
(Fig. 2D). Mice vaccinated with Aβ1–6CRM adjuvanted with AS01B
showed a further increase in the proportion of monocytes capturing Aβ;
the percentage of these cells was 9.98 (p = 0.0028), 11.90 (p b 0.0001),
4.55 (p = 0.0002) and 2.58 (p = 0.0007) times higher than in PBS,
Aβ1–6CRM, AS01B and Alum/Aβ1–6CRM treated mice, respectively
(Fig. 2D). Similar results were obtained for the analysis of Aβ levels per
cell, measured as the GMFI (Fig. 2E). In addition, AS01B/Aβ1–6CRM vacci-
nation had the greatest effect onpromotingAβuptake among total leuko-
cytes (Supplementary Fig. 2). ELISA performed on plasma samples
conﬁrmed that mice vaccinated with Aβ1–6CRM adjuvanted with AS01B
or Alum, but not those inoculated with controls, produced anti-Aβ anti-
bodies (Fig. 2A). Additionally, titers found in AS01B/Aβ1–6CRMvaccinated
micewere 5.64 (p=0.0055) foldsmore elevated than those obtained for
the Alum/Aβ1–6CRM group. Elevated antibody titers observed in the
AS01B/Aβ1–6CRM group correlate with the high Aβ uptake capacity char-
acterizing their bloodmonocytes. Interestingly, the number ofmonocytes
containing Aβ in mice receiving AS01B alone was 2.17 (p = 0.2628) and
2.59 (p = 0.0119) times higher than in PBS and Aβ1–6CRM controls, re-
spectively (Fig. 2D). These trends suggest that AS01B could potentiate
the ingestion of Aβ peptides by monocytes. These data also imply that
there could be an additive effect between the adjuvant used herein
(AS01B) and the antibodies, towards enhancing Aβ uptake bymonocytes
in vivo.
3.3. Anti-Aβ antibodies and AS01B adjuvant promote capture of Aβ by blood
monocytes ex vivo
To obtain additional insight into the capacity of peripheral blood
cells to capture Aβ, and to better understand the inﬂuence of vaccine
adjuvants on this activity, we performed the following ex vivo assay:
PBS, AS01B or Alum were administered to mice via IM injection. Blood
samples collected 24 h post-injection were incubated with vehiclemedia or with ﬂuorescent Aβ in the absence or presence of monoclonal
anti-Aβ antibodies (2E7). Blood cells were then stained to label surface
markers and analyzed by ﬂow cytometry. Single cells, cells without de-
bris and live cells were successively selected among acquired events for
analysis (Fig. 3A). Monocytes were identiﬁed as lineage (PE)-negative
(CD3e−, B220−, NK-1.1−, Ly-6G−) and CD11b (APC)-positive cells
(Fig. 3A), as previously described (Mildner et al., 2007). Their propor-
tion did not differ signiﬁcantly between the various tested conditions
(Fig. 3C). Approximately 21% of monocytes from PBS-injected mice
had taken up Aβ in the absence of anti-Aβ antibodies (Fig. 3B, D).
Under the same conditions, a similar proportion of Aβ-containing
monocytes was found in blood samples from Alum-injected mice,
whereas a slightly higher proportion was observed in blood samples
from AS01B-injected mice. Compared with monocytes from PBS- and
Alum-treated mice, the GMFI for ﬂuorescent Aβ in those from animals
receiving AS01B was increased by 1.26 fold (p b 0.01) (Fig. 3E). Interest-
ingly, the addition of anti-Aβ antibodies induced a 2.56 and 2.63 fold
(p b 0.0001) increase in the percentage of Aβ uptake in monocytes
from PBS- and Alum-treated mice, respectively (Fig. 3B, D). In the pres-
ence of anti-Aβ antibodies, the percentage of blood monocytes
capturing Aβ in samples from AS01B-injected mice increased by 3.61
fold (p b 0.0001). Additionally, incubation with 2E7 anti-Aβ antibodies
augmented the GMFI by 1.56, 2.38 and 1.52 folds, and the uptake score
by 4.0, 8.33 and 4.0 folds in samples from PBS-, AS01B- and Alum-
injectedmice, respectively (pb 0.0001) (Fig. 3E, F). In samples incubated
with anti-Aβ antibodies, the proportion of cells containing Aβ, however,
did not differ signiﬁcantly between those from PBS- and Alum-treated
mice. In contrast, when incubated with anti-Aβ antibodies, Aβ-
capturing monocytes were 1.64 (p = 0.0140) and 1.72 (p = 0.0066)
fold more prevalent in mice receiving AS01B than in PBS- and Alum-
treated mice. Moreover, the GMFI of monocytes from mice injected
with AS01B was 1.90 and 1.96 fold higher than the one found in
monocytes from PBS- and Alum-treated mice in samples incubated in
presence of 2E7 anti-Aβ antibodies (p b 0.0001) (Fig. 3E). Also, following
their incubation with 2E7 anti-Aβ antibodies, samples from
AS01B-inoculated mice had a 3.11 and 3.37 fold more elevated uptake
score than those from PBS- and Alum-injected mice, respectively
(p b 0.0001) (Fig. 3F). Additionally, the proportion of monocytes ex-
pressing CD80, MHC II and TLR-2 was signiﬁcantly increased in mice
injected with AS01B or AS01B/Aβ1–6CRM, but not in those receiving
Aβ1–6CRM or Alum/Aβ1–6CRM when compared with PBS-treated ani-
mals (Supplementary Fig. 3). This suggests that AS01B injection stimu-
lates the differentiation of monocytes into an active state. Together,
these data conﬁrm that blood monocytes can rapidly engulf Aβ. Nota-
bly, the uptake activity can be enhanced by anti-Aβ antibodies and by
prior administration of the immunostimulant AS01B. In this model,
AS01B triggers the activation of monocytes into a primed state, which
in turn, potentiate their Aβ uptake activity in the presence of anti-Aβ
antibodies.
3.4. Anti-Aβ antibodies stimulate cellular uptake and internalization of Aβ
through an actin polymerization-dependent mechanism
To better understand the mechanism underlying Aβ uptake, we
established in vitro assays to detect cellular amyloid content by immu-
noblotting. Our pilot experiments indicated that BV2 cells could incor-
porate amyloid peptides within 30 min of incubation with Aβ and that
addition of 2E7 anti-Aβ antibodies ampliﬁed the amount of Aβ
peptides associated with cells (data not shown). To further characterize
the mechanism of antibody-stimulated Aβ uptake, we performed the
following assay: BV2 cells were pre-incubated in the presence or
absence of an actin polymerization inhibitor (cytochalasin D). They
were then incubated for the indicated time with Aβ in the presence or
absence of anti-Aβ antibodies, cytochalasin D, or both (Supplementary
Fig. 4). Cells were subsequently washed to eliminate un-bound Aβ,
lysed, and analyzed by immunoblotting. We also analyzed cells that
Fig. 3. AS01B and anti-Aβ antibodies cooperate to stimulate the uptake of Aβ ex vivo. Mice were inoculated IMwith PBS, AS01B or Alum. Blood was harvested 24 h post-injection and in-
cubated with HiLyte Fluor 488 Aβ, HiLyte Fluor 488 Aβ in presence of 2E7 monoclonal anti-Aβ antibodies or vehicle media. Cells were then stained for cell-surface and viability markers,
and were examined by ﬂow cytometry. The successive selection of populations corresponding to single events, cells excluding debris, live cells and NK-1.1−B220−CD3e−Ly-6G−CD11b+
cells allowed the identiﬁcation of blood monocytes (A). The proportions of blood monocytes obtained in each sample tested under various conditions are shown in C. The proﬁle of
ﬂuorescent Aβ uptake, reﬂected by HiLyte Fluor 488 intensity, and obtained under various experimental conditions are shown in B. Monocytes positive for ﬂuorescent Aβwere identiﬁed
as Lineage-CD11b+A-beta+. A shift in populations harboring ﬂuorescently labeled Aβ was observed upon addition of this peptide with or without 2E7 antibodies and according to the
product injected into the animal prior to blood collection (B). The percentage of monocytes capturing Aβ and the GMFI of HiLyte Fluor 488 associated with Aβ-positive monocytes are
shown in D and E, respectively. The product of the percentage of Aβ-positive monocytes multiplied by the GMFI associated with these monocytes was expressed as an Aβ uptake score
(F) (Darrah et al., 2007). Each point represents an individual assay performed with an individual mouse. Assays performed with blood samples from PBS, AS01B or Alum injected mice
correspond to circle, triangle or diamond, respectively. Means ± SD are shown for each tested conditions. Presented values are from two independent experiments. Similar data were
obtained in four independent experiments.
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72 M. Hallé et al. / Journal of Immunological Methods 424 (2015) 64–79were trypsinized prior to lysis. This additional step facilitated the
distinction between internalized and surface-bound peptides, because
trypsin is known to cleave Aβ (Blennow et al., 2012), and therefore
remove non-internalized peptide. BV2 cells cultured in the absence of
cytochalasin D and not subjected to trypsin treatment prior to lysis
incorporated large quantities of Aβ, whichwere further increased by in-
cubation with 2E7 anti-Aβ antibodies (Fig. 4). Cells lysed under the
same conditions, but incubated with cytochalasin D, acquired slightly
smaller amounts of Aβ. Cells subjected to trypsin treatment also
contained Aβ at low levels. Incubation with both Aβ and anti-Aβ anti-
bodies increased the quantities of intracellular amyloid peptides. Nota-
bly, regardless of whether Aβ internalization was antibody-stimulated,
cytochalasin D almost completely abrogated Aβ uptake. Similar
observations were obtained using the microtubule polymerization in-
hibitor nocodazole (data not shown). These data indicate that anti-Aβ
antibodies stimulate cells to both bind and actively internalize Aβ.Additionally, the integrity of the cytoskeletal networks appeared to
play a major role in this phenomenon.
3.5. Cells process captured Aβ for degradation by taking advantage of the
IDE
To our knowledge, only limited information is available regarding
the stability of Aβ after antibody-stimulated uptake. To investigate
this, a pulse incubation was performed in the presence of Aβ alone or
with anti-Aβ antibodies, and BV2 cells were washed to eliminate un-
bound peptides, incubated in media free of amyloid for various periods
and analyzed by immunoblotting. Following the 30 min pulse incuba-
tion, cells had acquired appreciable levels of Aβ, which were increased
by incubation in the presence of anti-Aβ antibodies (Fig. 5A). Levels of
Aβ started to decrease after theﬁrst hour, but remained higher for a lon-
ger period in cells incubated in the presence of anti-Aβ antibodies.
These observations suggest that cells do not continue to accumulate
Aβ over a prolonged period of time; rather, Aβ levels diminish, possibly
due to intracellular Aβ degradation. A reverse correlation between the
activity of IDE or insulysin protease and the accumulation of Aβ was
described in murine models (Miller et al., 2003). To test the hypothesis
that an antibody-mediated increase in Aβ uptake leads to its degrada-
tion, we monitored the stability of Aβ in cells that had been subjected
to various conditions. First, cells were incubated with or without the
IDE pharmacological inhibitor 1, 10-phenanthroline. Then, cells in
presence of Aβ were incubated with or without anti-Aβ antibodies, 1,
10-phenanthroline or both. Subsequently, cells were washed to remove
uncaptured amyloid, were further incubated in absence of Aβ, with or
without 1, 10-phenanthroline, and were ﬁnally treated with trypsin,
lysed and analyzed by immunoblotting (Supplementary Fig. 5). Three
hours after the pulse incubation with Aβ alone or Aβwith 2E7 anti-Aβ
antibodies, we observed a reduction in cellular Aβ content, as expected
(Fig. 5B). Cells incubated with 1, 10-phenanthroline displayed an
attenuated reduction of Aβ following a 3 hours incubation period,
particularly when they were incubated in presence of the 2E7 anti-Aβ
antibodies (Fig. 5B). These data imply that intracellular Aβ is degraded
following its uptake and exemplify the IDE peptidase as an enzymatic
machinery mediating this process.
3.6. Monoclonal antibodies and plasma from mice vaccinated with AS01B
and Aβ peptide stimulate the phagocytosis of large Aβ particles in vitro
The process of phagocytosis occurs when a cell engulfs a particle of
0.5 μm or larger (Desjardins and Grifﬁths, 2003). Since Aβ peptides
interact to form molecular complexes and particles of diverse sizes,
we tested whether antibody-stimulated uptake of amyloid could be
applied to larger aggregates. For this purpose, NeutrAvidin-labeled
latex beads (1 μm) coated with Aβ42-biotin were incubated with
THP-1 cells for different periods and in the presence of various antibod-
ies. The analysis of THP-1 cells culturedwith Aβ-coated beads, following
the exclusion of both doublets and debris, allowed the detection of
phagocytic cells (Fig. 6A, B). The proportion of cells engulﬁng beads
increased in a time-dependent manner (Fig. 6B, C, D, E). No phagocytic
activity was detected in cells incubated under control conditions
(Fig. 6B, C, D, E, F). Cells incubated with beads in the presence of mono-
clonal anti-Aβ antibodies (both 2E7 and 6E10) presented signiﬁcantly
increased phagocytic activity as compared with those incubated with
beads alone or beads with non-speciﬁc immunoglobulins (Fig. 6B, C).
Notably, signiﬁcant increased phagocytosis was observed for cells incu-
bated with anti-Aβ antibodies at each tested time point (p b 0.005).
Moreover, treatment with plasma from AS01B/Aβ1–6CRM-vaccinated
animals, but not with plasma from control (PBS) animals, signiﬁcantly
ampliﬁed the phagocytic response (p b 0.0001) (Fig. 6D, E). The poten-
tiation of phagocytic activity was conﬁrmed using equivalent volumes
of plasma from individual mice subjected to control or Aβ1–6CRM/
AS01B vaccination (Fig. 6F). Indeed, the proportion of THP-1 cells
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Fig. 4.Antibodies stimulate cellular uptake and internalization of Aβ through amechanismdependent on cytoskeletal integrity. As detailed inmaterials andmethods, cells were incubated
with vehicle media or cytochalasin D, and then, further incubatedwith vehicle media, Aβ alone, Aβwith 2E7 anti-Aβ antibodies, cytochalasin D alone, Aβwith cytochalasin D, or Aβwith
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(p b 0.0001) in cells incubated with beads and plasma samples from
AS01B/Aβ1–6CRM-immunized mice than in cells receiving beads alone
or beads with plasma samples from PBS-inoculated mice, respectively
(Fig. 6F). Internalization of ﬂuorescent Aβ-coated beads by THP-1 cells
was conﬁrmed using phase contrast and ﬂuorescence microscopy.
THP-1 cells associated with one or multiple Aβ-coated beads were ob-
served at lower magniﬁcation. In addition, at higher magniﬁcation,
Aβ-coated beads were found in the cytosol and on the periphery of
the nucleus of THP-1 cells (Supplementary Fig. 6C and data not
shown). Analyses of phagocytic cells, which are visualized on ﬂuores-
cence intensity histograms revealed that the GMFI of the second, third,
fourth and following peaks corresponded to multiples of the GMFI of
the ﬁrst peak (Supplementary Fig. 6A, Supplementary Table 1). Also,
the granularity associated with each peak slightly increased with the
raised GMFI (Supplementary Fig. 6B). Since the beads were of relatively
uniform size, we concluded that each peak corresponded to a particular
number of beads acquired per cell. This approach facilitated a more
detailed characterization of the phagocytic activity in the presence of
various products andmade it possible to performmultiple comparisons
between populations engulﬁng one, two, three, four, ﬁve, or more than
ﬁveAβ-coated beads (Supplementary Fig. 6D, E, J). Cells phagocytizing a
single bead were also compared with those engulﬁng multiple beads
(Supplementary Fig. 6F, G, H, I, K). For example, in the case of cells incu-
bated with anti-Aβ antibodies, while the percentage of cells containing
a single bead stabilized at later time points, the proportion of those
ingesting more than ﬁve or multiple microspheres kept increasing
(Supplementary Fig. 6D, E, H, I). Together, these results illustrate that
antibody-driven Aβ uptake can stimulate the phagocytosis of large
Aβ-coated particles.
4. Discussion
The general impairment in clearing Aβ in LOAD patients
(Mawuenyega et al., 2010) correlates with a decreased capacity of
their monocytes and macrophages to phagocytize Aβ (Fiala et al.,
2005; Avagyan et al., 2009). Here, we explored the ability of various
strategies to facilitate cell-mediated capture of Aβ and we described
novel approaches to investigate the uptake and phagocytosis of Aβ.
This toxic peptide was readily available in the plasma of TASTPM mice
and was naturally captured by blood monocytes throughout their
lifespan. Vaccinations with adjuvanted Aβ1–6CRM antigen, which effec-
tively elevated antibody production, enhanced the rapid uptake of Aβ
by monocytes in vivo. Additional ex vivo analyses emphasized theimportance of innate immunity activation to mediate optimal cellular
sequestration of Aβ. For example, the immunostimulant AS01B, but
not Alum, could efﬁciently amplify the antibody-stimulated uptake of
Aβ. Interestingly, Aβ-speciﬁc antibodies facilitated theuptake and inter-
nalization of amyloid peptides. Additionally, our in vitro system
illustrated that engulfed Aβ and Aβ/antibody complexes could be de-
graded via a mechanism involving the IDE peptidase. Cellular uptake
of Aβ could also be extended to the phagocytosis of larger (1 μm)
Aβ-coated particles, a phenomenon that was enhanced by plasma
from Aβ-immunized animals and Aβ-speciﬁc monoclonal antibodies.
Amyloid deposition has been previously observed in the TASTPM
murine AD model at 3 months old (Howlett et al., 2004). In our study,
Aβ levels were detectable in the plasma of TASTPM mice between 1
and 13 months of age. Likewise, Aβ has been detected in the plasma
of various transgenic models, including PDAPP, APP-PS1, Tg-CRND8,
and Tg2576 (DeMattos et al., 2001, 2002; Barten et al., 2005; Burgess
et al., 2006). Findings from clinical studies have also described the
presence of Aβ in the plasma of AD patients (Tamaoka et al., 1996;
Mayeux et al., 1999, 2003; Assini et al., 2004; Schupf et al., 2008). A
number of investigations have reported a reduction of the Aβ levels in
the plasma as AD progresses (Schupf et al., 2008; Devanand et al.,
2011). These reports and others suggest that circulating Aβ levels di-
minish due to the inﬂux of Aβ into the brain, where it binds to neurones
or is integrated into growing plaques (Clifford et al., 2007; Devanand
et al., 2011). In this report, ﬂuctuations in plasma Aβ levels were ob-
served over the lifespan of TASTPM mice, with Aβ levels being higher
in younger than in older mice. These similarities between the patients
and the transgenic mice support the physiological relevance of animal
models to study the presence and regulation of circulating Aβ. Our
analysis of blood monocytes from TASTPM mice revealed the presence
of intracellular Aβ, and both the proportion of Aβ-positive cells and
the levels of Aβ in these cells tended to increase with time. This rise in
cellular sequestration of Aβmay partly explain the observed decrease
of Aβ levels in the blood. Despite the constant presence of Aβ in the
blood, approximately 20% of monocytes remained negative for the
analyzed peptide. It is possible that permanent contact with Aβ
desensitized these cells and reduced their phagocytic activity. This
reduced cellular uptake of Aβ is in line with previous ﬁndings in AD pa-
tients (Fiala et al., 2005; Avagyan et al., 2009). These results emphasize
the importance of developing approaches to optimize cell-mediated
clearance of Aβ.
The stimulation of various pathwaysmodulating the innate immune
response may be a potential approach to promote Aβ elimination. For
example, transgenic AD mice receiving the cytokine macrophage
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Fig. 5. Cellular uptake of Aβ is facilitated by speciﬁc antibodies and is followed by its degradation, which involves IDE. To examine the stability of incorporated Aβ, cells were incubated for
30 min with amyloid peptides in the presence or absence of 2E7 antibodies. The media was then replaced, and cells were further incubated in absence of Aβ. Proteins were extracted
following different incubation times and were analyzed by immunoblotting using anti-Aβ and anti-actin antibodies (A). To evaluate the contribution of the IDE peptidase, cells were
pre-incubated with the pharmacological inhibitors 1, 10-phenanthroline. Then, cells were incubated for 30min with Aβ in the presence or absence of 2E7 antibodies and in the presence
of 1, 10-phenanthroline in various conditions, as indicated. Cellswere subsequently incubated in the absence of Aβ, but including or lacking 1, 10-phenanthroline, for a speciﬁed time. Cells
were ﬁnally washed, detached using trypsin, washed, lysed and analyzed by immunoblotting (B). Results are representative of two independent experiments.
74 M. Hallé et al. / Journal of Immunological Methods 424 (2015) 64–79colony-stimulating factor were protected against cognitive decline and
Aβ accumulation (Boissonneault et al., 2009). TLR pathways have also
been shown to promote cell-mediated Aβ clearance. Indeed, inactiva-
tion of the TLR2 gene in an AD murine model exacerbated cognitive
defects and increased the accumulation of Aβ in the brain (Richard
et al., 2008), and destructive mutation of TLR4 in a similar model
increased the accumulation of Aβ (Tahara et al., 2006). Interestingly,
the incubation of microglial cells with ligands speciﬁc for TLR2, TLR4 or
TLR9 elevated Aβ uptake by these cells (Tahara et al., 2006). Additionally,
intrahippocampal injections of lipopolysaccharide (LPS) activated mi-
croglia to reduce diffuse Aβ deposits in Tg2576 mice (Herber et al.,
2004, 2007). Moreover, intranasal immunization with the proteosome-
based adjuvant and TLR2 agonist Protollin was also shown to decrease
amyloid plaque formation in correlation with microglial activation
(Chabot et al., 2007; Frenkel et al., 2008). Despite these beneﬁcial effects,
cellular-mediated clearance of Aβ may also elicit adverse side effects.
During the uptake of ﬁbrillar Aβ, microglia produced and released reac-
tive oxygen species (ROS) through a process requiring the Vav guaninenucleotide exchange factor (Wilkinson et al., 2006). Oxidative stress rep-
resents an important biochemical event and risk factor contributing to
neurodegeneration in AD (Quintanilla et al., 2012; Yan et al., 2013). Ac-
cordingly, products promoting the cell-mediated elimination of Aβ in a
context that minimizes ROS production could be critical for the
development of a safe and effective treatment for AD. We recently iden-
tiﬁedMPL as a TLR4 activator that protects cognitive functions and favors
Aβ elimination in APPswe/PS1 mice (Michaud et al., 2013). These pheno-
types correlated with the ability of MPL to increase Aβ uptake activity
and to stimulate the expansion of blood monocytes (Michaud et al.,
2013). In contrast with LPS, MPL did not induce cyclooxygenase-2 or in-
ducible nitric oxide synthase expression, nor the production of nitrite
(Michaud et al., 2013). In the current study, we examined the effect of
the MPL-containing Adjuvant System AS01B on the cellular uptake of
Aβ. Injection of amyloid antigen formulated with AS01B efﬁciently stim-
ulated the synthesis of high titers of anti-Aβ antibodies. Although AS01B
did not signiﬁcantly alter the number of bloodmonocytes, it augmented
their expression of CD80,MHC II and TLR-2, and their capacity to capture
75M. Hallé et al. / Journal of Immunological Methods 424 (2015) 64–79Aβ. Importantly, AS01B enhanced the ability of monocytes to engulf Aβ
both ex vivo and in vivo. This effect was particularly pronounced in the
presence of anti-Aβ antibodies. Together, these data support a cumula-
tive effect between an immunostimulant and antibodies to promote
cell-mediated clearance of Aβ. Therefore, the development andmonitor-
ing of immunotherapies promoting both the participation of anti-Aβ
antibodies and the stimulation of phagocytic activity in monocytes may
beneﬁt the development of novel and effective strategies to prevent AD.
Intracranial injection of anti-Aβ antibodies in transgenic animals
accelerates the removal of Aβ deposition from the brain (Wilcock
et al., 2003, 2004a). Passive immunotherapy, involving the peripheral
injection of antibodies targeting Aβ, also reduces the accumulation of
amyloid and improves cognitive functions of AD murine models (Bard
et al., 2000; Wilcock et al., 2004b). Even though peripherally adminis-
tered anti-Aβ antibodies have been found to be associated with plaques
in the brain (Bard et al., 2000; Wilcock et al., 2004b), only a small frac-
tion of the administered antibodies seemed to successfully cross the
blood–brain barrier (Banks et al., 2002). However, circulating antibodiesFig. 6. Anti-Aβ antibodies stimulate the phagocytosis of 1 μmAβ-coated latex beads. To evaluat
dicated periodwith 1 μmAβ-coatedmicrosphereswith orwithout puriﬁedmonoclonal antibod
ﬂow cytometry. Doublets and debris were excluded and, among selected cells, phagocytic cells
phagocytic cells for various treatments are shown in B andD. The effect of plasma from different
phagocytic activity towards Aβ-coated was tested (F). Each point represents an assay performe
(Beads alone) correspond to open andﬁlled circles, respectively. Conditions involving 2E7 anti-A
plasma fromAβ1–6CRM/AS01B vaccinatedmice are represented by diamonds, inverted triangles
tested conditions. Data are representative of three independent experiments.can sequester plasma Aβ and reduce cerebral amyloid loads (DeMattos
et al., 2001, 2002). Circulating monocytes may be involved in the cell-
mediated clearance of Aβ, complementing the activity of microglia. In
the current study, blood monocytes from TASTPM mice were consis-
tently positive for Aβ. Furthermore, immunization involving speciﬁc an-
tibodies and AS01B stimulated de novo Aβ capture by monocytes. Bard
et al. (2003) have shown that IgG2a antibodies recognizing amyloid
N-terminal epitopes were more effective in triggering Aβ phagocytosis
(Bard et al., 2003). Our observations involving the 2E7 antibodies as
well as adjuvanted Aβ1–6CRM vaccines correlate with their ﬁndings.
We used a biochemical approach to further investigate the mecha-
nism of Aβ uptake in the presence of anti-Aβ antibodies. The results
showed that Aβ uptake and internalization increased in the presence of
amyloid-speciﬁc antibodies, consistentwith our in vivo and ex vivo assays.
Experiments performedbyMandrekar et al. (2009) illustrate thatmicrog-
lia capture soluble Aβ via a cytoskeletal-dependent macropinocytosis
event (Mandrekar et al., 2009). Our in vitro assays also highlighted
the need of functional actin polymerization for the internalization ofe the phagocytosis of large amyloid particles, THP-1 monocytes were incubated for the in-
ies (B, C) or plasma fromvaccinated animals (D, E). Cells were then ﬁxed andmonitored by
positive for ﬂuorescent beads signals were identiﬁed (A, B, D). The ﬂuorescent proﬁles of
individual mice subjected to control (PBS) or Aβ1–6CRM/AS01B vaccination on THP-1 cells
d independently. THP-1 cells incubated under control conditions or with Aβ-coated beads
β antibodies, 6E10 anti-Aβ antibodies, non-speciﬁc IgG, plasma fromPBS treated-mice and
,ﬁlled squares, opened squares and triangles, respectively.Means±SD are shown for each
Fig. 6 (continued).
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internalized amyloid diminished with time in cells further incubated
without Aβ, suggesting the potential degradation of intracellular
peptides. Importantly, inhibition of IDE as well as phagolysosomal
alkilinization promoted the extended accumulation of Aβ in cells incubat-
ed in media free of amyloid peptide (Fig. 5C and unpublished results).
This effect was further potentiated in cells that also received anti-Aβ
antibodies. These ﬁndings conﬁrm the functional relevance of the co-
localization of Aβ and phagolysosomal markers in microglia (Hjorth
et al., 2010; Michaud et al., 2013) and data not shown), and are in line
with the identiﬁcation of IDE as an amyloid-degrading enzyme (Farris
et al., 2003;Miller et al., 2003). Together, these biochemical analyses indi-
cate that speciﬁc antibodies promote cellular uptake and internalization
of Aβ, leading to amyloid degradation.
The proteolysis of APP generates free Aβ peptides that self-assemble
into various products, such as oligomers, amylospheroids, protoﬁbrils, ﬁ-
brils and several other aggregates (Noguchi et al., 2009; Roychaudhuri
et al., 2009; Pryor et al., 2012). Aβ can also bind with hemoglobin, apoE,
and other molecules that may form part of, or modulate the formation
of, these aggregates (Kuo et al., 1999; Oyama et al., 2000; Wu et al.,
2004; Chuang et al., 2012; Liu et al., 2014). Additionally, the presence of
metal ions can modify the rate of assembly, as well as the morphology,
of resulting aggregates (Innocenti et al., 2010; Tiiman et al., 2013).
Given the unfolded native conformation of Aβ (Roychaudhuri et al.,
2009), amyloid complexes are likely to exist in an array of sizes and com-
positions within the highly intricate in vivo environment. To investigatethe phagocytosis of larger Aβ complexes in settings that would circum-
vent interferences from the macropinocytosis of smaller forms of Aβ,
we employed a bead system allowing the production of ﬂuorescent and
uniform amyloid-coated particles. Synthetic microspheres are also a rec-
ognized tool to investigate phagocytosis (Desjardins and Grifﬁths, 2003).
Using this technology, we observed that THP-1 monocytes could rapidly
phagocytize beads coveredwithAβ. Incubationof the cellswithmonoclo-
nal anti-Aβ antibodies or with serum from animals vaccinated with
AS01B/Aβ1–6CRM, but not with control antibodies or sera, strongly ampli-
ﬁed this phagocytic response. This experimental design simpliﬁes the
analysis of the phagocytic activitymagnitude. Indeed, theﬂuorescence in-
tensity for each phagocytic population corresponded to a multiple of the
GMFI for the positive cells containing the lowest number of beads. This
suggests that each separate phagocytic population corresponded to a par-
ticular number of engulfed beads per cell. These data support the phago-
cytosis of a wide range of Aβ-containing particles by monocytes.
Together, results and proposed methods herein emphasize the
importance of monitoring cellular activity to capture Aβ in the context
of AD and AD immunotherapy. Defective phagocytic activity has been
reported in monocytes from AD patients, which contrasted with those
from healthymatch controls (Fiala et al., 2005). This immunodeﬁciency
supports the necessity to produce active vaccine approaches promoting
phagocytic activity. We believe that such immunotherapy involving
cell-mediated capture and degradation of Aβwill be improved by con-
ditions combining both an immunostimulant and anti-Aβ speciﬁc anti-
bodies. Interestingly, the reduction of plaque accumulation observed in
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77M. Hallé et al. / Journal of Immunological Methods 424 (2015) 64–79the brains of patients treated with the prototype vaccine AN1792 and
the stabilization of memory loss within the higher antibody responders
support the viability of immunological approaches to treat AD (Nicoll
et al., 2003; Ferrer et al., 2004; Masliah et al., 2005; Holmes et al.,
2008). In addition, analyses of phase III trials involving solaneuzumab
demonstrated a decreased cognitive decline in patients with mild AD
(Tayeb et al., 2013). Interestingly, these studies showed increased levels
of Aβ in the plasma of treated individuals, which supports the effect of
the peripheral sink hypothesis in patients (Tayeb et al., 2013). Strategies
that optimize the peripheral clearance of amyloid may thus prove valu-
able in improving upcoming therapies for AD. Ex vivo assays involving
brain sections of transgenic mice have been used previously to investi-
gate the phagocytosis of amyloid deposits by microglia (Bard et al.,
2000, 2003). Here, we developed additional methodologies to
investigate and characterize the uptake and phagocytosis of Aβ. Using
these procedures, we showed that speciﬁc immunostimulants as well
as anti-Aβ antibodies can cooperate to stimulate the uptake and phago-
cytosis of Aβ, a process ultimately leading to its degradation. This ap-
proach could ﬁnd implications in future immunotherapies, and could
be used to develop new assays and biomarkers tomonitor the immuno-
logical response to candidate therapeutics.Author's disclosures
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